Apotheca Biosciences, Inc.

CIK:0001632053|SEC Filings

CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED) - USD ($)	2 Months Ended	3 Months Ended
	Apr. 30, 2018	Apr. 30, 2019
Income Statement [Abstract]
Revenues	$ 0	$ 0
Operating Expenses
Personnel expenses	30,000	112,672
Marketing and Design, related party	0	24,000
General and administrative	8,242	63,540
General and administrative, related party	0	35,268
Stock-based compensation	0	63,600
Total operating expenses	38,242	299,080
Net loss from operations	(38,242)	(299,080)
Other income (expenses):
Interest expense	0	(71,848)
Interest expense, related party	0	(3,092)
Derivative income	0	371,349
Total other income (expense)	0	296,409
Net loss	$ (38,242)	$ (2,671)
Basic and diluted loss per share	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding	37,752,809	118,243,201

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED) - USD ($)	2 Months Ended	3 Months Ended
	Apr. 30, 2018	Apr. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (38,242)	$ (2,671)
Changes in working capital requirements
Depreciation expense	0	(371,379)
Depreciation and amortization expense	0	331
Stock issued for services	6,000	63,600
Amortization of debt discount	0	65,227
Increase (decrease) in:
Prepaid expenses	0	917,034
Inventory	0	(96,047)
Accounts payable	295	0
Accounts payable - related party	296	7,795
Related party advances	1,947	24,050
Accrued expenses	0	102,255
Accrued expenses - related party	30,000	0
Net cash (used in) provided by operating activities	296	(105,673)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of furniture and equipment - related party	0	(1,791)
Net cash used in investing activities	0	(1,791)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes payable	0	355,000
Net cash provided by financing activities	0	355,000
NET INCREASE IN CASH	296	247,536
CASH, BEGINNING OF PERIOD	0	2,942
CASH, END OF PERIOD	296	250,478
Supplemental disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Noncash operating and financing activities:
Beneficial conversion feature on convertible notes payable	0	8,485
Stock issued in satisfaction of accounts payable	$ 0	$ 7,980

CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Apr. 30, 2019	Jan. 31, 2019
Current assets
Cash	$ 250,478	$ 2,942
Inventory	103,687	7,640
Deposits and prepaids (including related party rent of $6,000)	6,600	98,302
Total current assets	360,765	108,884
Right to use asset - related party	133,810	0
Equipment, furniture and fixtures (including purchase from related party $2,508) net of accumulated depreciation	7,905	6,441
Intangible assets, net of accumulated amortization	570	0
Total fixed assets, net	142,285	6,441
Total Assets	503,050	115,325
Current liabilities
Accounts payable	27,944	24,104
Accounts payable, related parties	16,020	8,225
Accrued liabilities	159,281	82,770
Accrued liabilities, related party	5,592	0
Notes payable	18,600	18,600
Related party advances	24,050	0
Derivative liabilities	656,936	771,918
Lease liability - related party, current portion	108,591	0
Convertible note payable	165,159	26,261
Total current liabilities	1,182,173	931,878
Lease liability - related party, less current portion	30,560	0
Total Liabilities	1,212,733	931,878
Shareholders' Deficit
Common stock: 600,000,000 authorized; $0.001 par value at April 30, 2019 and 200,000,000 authorized, $0.0001 par value at January 31, 2019 118,840,795 and 118,214,000 shares issued and outstanding at April 30, 2019 and January 31, 2019, respectively	118,841	118,214
Additional paid in capital	1,596,043	1,503,973
Shares to be issued, common shares	90,544	73,700
Accumulated deficit	(2,515,111)	(2,512,440)
Total Shareholders' Deficit	(709,683)	(816,553)
Total Liabilities and Shareholders' Deficit	$ 503,050	$ 115,325